SCHEMBL901700

SCHEMBL901700

Clc1ccc(C(Cl)Cl)s1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9830633 0.79
SCHEMBL680633 0.76
SCHEMBL7996347 0.76
SCHEMBL12204156 0.76 GABBR2 (0.40)
SCHEMBL9522198 0.76 TOP2A (0.45)
SCHEMBL12711981 0.72 GABBR2 (0.38)
SCHEMBL1239420 0.72
SCHEMBL7036365 0.70 GABBR2 (0.37)
SCHEMBL20032385 0.70 GABBR2 (0.49)
SCHEMBL15898103 0.70 DAO (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3590942-B1 HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR FUJIAN COSUNTER PHARMACEUTICAL CO LTD (CN) 2021-06-09 EP disclosed
EP-3590942-B1 HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR FUJIAN COSUNTER PHARMACEUTICAL CO LTD (CN) 2021-06-09 EP disclosed
US-11008331-B2 Hepatitis B virus surface antigen inhibitor FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) 2021-05-18 US disclosed
US-11008331-B2 Hepatitis B virus surface antigen inhibitor FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) 2021-05-18 US disclosed
US-20200039995-A1 HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) 2020-02-06 US disclosed
US-20200039995-A1 HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) 2020-02-06 US disclosed
CN-109071564-B Hepatitis B virus surface antigen inhibitors 福建广生堂药业股份有限公司 2019-08-27 CN disclosed
CN-109071564-A Hepatitis B virus surface antigen inhibitors 福建广生堂药业股份有限公司 2018-12-21 CN disclosed
US-20160257697-A1 THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OFUSE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2016-09-08 US disclosed
US-20160257697-A1 THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OFUSE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2016-09-08 US disclosed
WO-2014110706-A1 THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2014-07-24 WO disclosed
WO-2014110688-A1 THIOPHENE- SUB STITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2014-07-24 WO disclosed
CN-103459399-A Tetracyclic indole derivatives for the treatment of hepatitis C virus infection MERCK SHARP & DOHME 2013-12-18 CN disclosed
EP-2621931-A1 TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION Merck Sharp & Dohme Corp. (US) 2013-08-07 EP disclosed
WO-2012041014-A1 TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION MERCK SHARP & DOHME CORP. (US) 2012-04-05 WO disclosed
WO-2012041014-A1 TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION MERCK SHARP & DOHME CORP. (US) 2012-04-05 WO disclosed